In the electrophysiology mapping and ablation devices market, ongoing innovations have revolutionized cardiac care. Advanced mapping technologies provide precise insights into heart rhythm disorders, enabling tailored treatment. Ablation devices offer minimally invasive solutions, reducing the need for open-heart surgery. Benefits of electrophysiology mapping and ablation devices include enhanced patient outcomes, shorter recovery times, and improved quality of life. These innovations have made cardiac procedures safer, more effective, and accessible to a broader patient base, marking a significant advancement in electrophysiology.
Access Full Report@ https://www.databridgemarketresearch.com/fr/reports/asia-pacific-electrophysiology-mapping-and-ablation-devices-market
Data Bridge Market Research analyses that the Asia-Pacific Electrophysiology Mapping and Ablation Devices Market, which was USD 2,180.360 million in 2022, is expected to reach USD 4,917.10 million by 2030, at a CAGR of 10.7% during the forecast period 2023 to 2030. As healthcare infrastructure in developing regions grows, it extends the availability of advanced electrophysiology mapping and ablation devices, granting previously underserved populations access to modern, life-saving cardiac care and procedures.
Key Findings of the Study
Aging population is expected to drive the market's growth rate
The electrophysiology mapping and ablation devices market experiences increased demand driven by the aging population. With age comes a higher likelihood of heart-related conditions, such as arrhythmias and atrial fibrillation, necessitating advanced diagnostic and therapeutic solutions. As the elderly demographic expands, so does the market for these devices, as they play a crucial role in diagnosing and treating age-related heart conditions, highlighting the market's growth potential and relevance in addressing the healthcare needs of an aging population.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Ablation Devices and Electrophysiology Mapping), Indication (Cardiology, Cancer, Cosmetic Surgery, Gynecology, Oncology, Ophthalmology, Orthopedic Treatment, Pain Management, Urology, Atrial Flutter, Atrioventricular Nodal Reentry Tachycardia (AVNRT), Atrial Fibrillation, Wolff-Parkinson-White Syndrome (WPW) and Others), Function (Conventional. Advanced, Cryoablation, Microwave and Ultrasound), Procedure (Aesthetics-Skin Rejuvenation and Tightening, Aesthetics-Body Sculpting, Fat Reduction, and The Minimization In The Appearance Of Cellulite, Benign Prostatic Hyperplasia, Transurethral Needle Ablation, Laser And Other Energy-Based Therapies/Holmium Laser Ablation/Enucleation of The Prostate, Stress Urinary Incontinence, Menorrhagia/Endometrial Ablation, Uterine Fibroids, Spinal Decompression And Denervation, Varicose Veins, Atrial Fibrillation, Tumor Ablation and Others), End-User (Hospitals, Ambulatory Surgery Center, Diagnostic Center, Cardiac Catheterization Laboratories, Specialty Clinics and Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
|
|
Market Players Covered
|
Abbott (U.S.), Arthrex, Inc. (U.S.), TORAY INDUSTRIES, INC. (U.S.), Olympus Corporation (Japan), Teleflex Incorporated (U.S.), MicroPort Scientific Corporation (China), BIOTRONIK SE & Co. KG. (Germany), Boston Scientific Corporation (U.S.), GE Healthcare (U.S.), Siemens Healthineers AG (Germany), Japan Lifeline Co., Ltd. (Japan), STARmed Co., Ltd. (South Korea), Koninklijke Philips N.V. (Netherlands), Surgnova (China), Medtronic (Ireland)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Asia-Pacific electrophysiology mapping and ablation devices market is segmented on the basis of type, indication, function, procedure, and end user.
- On the basis of type, the Asia-Pacific electrophysiology mapping and ablation devices market is segmented into ablation devices, and electrophysiology mapping.
- On the basis of indication, the Asia-Pacific electrophysiology mapping and ablation devices market is segmented into cardiology, cancer, cosmetic surgery, gynecology, oncology, ophthalmology, orthopedic treatment, pain management, urology, atrial flutter, atrioventricular nodal reentry tachycardia (AVNRT), atrial fibrillation, wolff-parkinson-white syndrome (WPW), and others.
- On the basis of function, the Asia-Pacific electrophysiology mapping and ablation devices market is segmented into conventional. advanced, cryoablation, microwave, and ultrasound.
- On the basis of procedure, the Asia-Pacific electrophysiology mapping and ablation devices market is segmented into aesthetics-skin rejuvenation and tightening, aesthetics-body sculpting, fat reduction, and the minimization in the appearance of cellulite, benign prostatic hyperplasia, transurethral needle ablation, laser and other energy-based therapies/holmium laser ablation/enucleation of the prostate, stress urinary incontinence, menorrhagia/endometrial ablation, uterine fibroids, spinal decompression and denervation, varicose veins, atrial fibrillation, tumor ablation and others
- On the basis of end user, the Asia-Pacific electrophysiology mapping and ablation devices market is segmented into hospitals, ambulatory surgery center, diagnostic center, cardiac catheterization laboratories, specialty clinics, and others.
Major Players
Data Bridge Market Research recognizes the following companies as the Asia-Pacific electrophysiology mapping and ablation devices market players in Asia-Pacific electrophysiology mapping and ablation devices market are Abbott (U.S.), Arthrex, Inc. (U.S.), TORAY INDUSTRIES, INC. (U.S.), Olympus Corporation (Japan), Teleflex Incorporated (U.S.), MicroPort Scientific Corporation (China), BIOTRONIK SE & Co. KG. (Germany).
Market Developments
- In 2020, Siemens Healthineers AG launched the ACUSON Redwood Ultrasound System in India, a cutting-edge device with cardiology mapping and lesion identification and diagnosis applications. This strategic move expanded the company's product portfolio, thereby stimulating the Asia-Pacific market for electrophysiology mapping and ablation devices. The innovative ultrasound system enhanced the capabilities available to healthcare professionals, contributing to the advancement of cardiac care in the region.
- In February 2022, Medtronic announced that it is Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters received FDA-extended approval for treating juvenile Atrioventricular Nodal Reentrant Tachycardia (AVNRT). These catheters are the first and only devices licensed for this purpose, addressing the growing prevalence of AVNRT in younger patients. This development marks a significant advancement in cardiac ablation technology for pediatric care.
- In January 2022, Abbott Laboratories, a pharmaceutical company, revealed that the U.S. Food and Drug Administration (USFDA) granted clearance for the EnSite X Electrophysiology system featuring EnSite omnipolar technology. This advanced system is approved for treating atrial fibrillation, a common heart rhythm disorder. The clearance signifies a significant step in improving the diagnosis and treatment of atrial fibrillation, enhancing patient care and outcomes.
Regional Analysis
Geographically, the countries covered in the Asia-Pacific electrophysiology mapping and ablation devices market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
As per Data Bridge Market Research analysis:
Japan is the dominant region in Asia-Pacific electrophysiology mapping and ablation devices market during the forecast period 2023-2030
Japan dominates the Asia-Pacific electrophysiology mapping and ablation devices market is attributed to substantial investments in research and development, particularly in radiofrequency ablation and electrophysiology mapping devices. This focus on innovation has resulted in the country producing advanced technologies that cater to the growing demand for precise and effective treatments in cardiology and electrophysiology. As a result, Japan leads the region regarding technological advancements and market dominance.
For more detailed information about the Asia-Pacific electrophysiology mapping and ablation devices market report, click here – https://www.databridgemarketresearch.com/fr/reports/asia-pacific-electrophysiology-mapping-and-ablation-devices-market
